UWSpace is currently experiencing technical difficulties resulting from its recent migration to a new version of its software. These technical issues are not affecting the submission and browse features of the site. UWaterloo community members may continue submitting items to UWSpace. We apologize for the inconvenience, and are actively working to resolve these technical issues.
 

Towards principled design of cancer nanomedicine to accelerate clinical translation

Simple item page
dc.contributor.authorSouri, Mohammad
dc.contributor.authorSoltani, M.
dc.contributor.authorKashkooli, Farshad Moradi
dc.contributor.authorShahvandi, Mohammad Kiani
dc.contributor.authorChiani, Mohsen
dc.contributor.authorShariati, Fatemeh Sadat
dc.contributor.authorMehrabi, Mohammad Reza
dc.contributor.authorMunn, Lance L.
dc.date.accessioned2022-02-04T21:45:10Z
dc.date.available2022-02-04T21:45:10Z
dc.date.issued2022-01
dc.description.abstractNanotechnology in medical applications, especially in oncology as drug delivery systems, has recently shown promising results. However, although these advances have been promising in the pre-clinical stages, the clinical translation of this technology is challenging. To create drug delivery systems with increased treatment efficacy for clinical translation, the physicochemical characteristics of nanoparticles such as size, shape, elasticity (flexibility/rigidity), surface chemistry, and surface charge can be specified to optimize efficiency for a given application. Consequently, interdisciplinary researchers have focused on producing biocompatible materials, production technologies, or new formulations for efficient loading, and high stability. The effects of design parameters can be studied in vitro, in vivo, or using computational models, with the goal of understanding how they affect nanoparticle biophysics and their interactions with cells. The present review summarizes the advances and technologies in the production and design of cancer nanomedicines to achieve clinical translation and commercialization. We also highlight existing challenges and opportunities in the field.en
dc.identifier.urihttps://doi.org/10.1016/j.mtbio.2022.100208
dc.identifier.urihttp://hdl.handle.net/10012/18052
dc.language.isoenen
dc.publisherElsevieren
dc.relation.ispartofseriesMaterials Today Bio;
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjecttumor microenvironmenten
dc.subjectnanomedicineen
dc.subjectdrug deliveryen
dc.subjectnanoparticle designen
dc.subjectdrug loadingen
dc.subjectclinical translationen
dc.titleTowards principled design of cancer nanomedicine to accelerate clinical translationen
dc.typeArticleen
dcterms.bibliographicCitationSouri, M., Soltani, M., Kashkooli, F. M., Shahvandi, M. K., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022). Towards principled design of cancer nanomedicine to accelerate clinical translation. Materials Today Bio, 100208. https://doi.org/10.1016/j.mtbio.2022.100208en
uws.contributor.affiliation1Faculty of Engineeringen
uws.contributor.affiliation2Centre for Bioengineering and Biotechnology (CBB)en
uws.contributor.affiliation2Electrical and Computer Engineeringen
uws.peerReviewStatusRevieweden
uws.scholarLevelFacultyen
uws.typeOfResourceTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Towards principled design of cancer nanomedicine to accelerate clinical translation.pdf
Size:
3.63 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.47 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Waterloo Research
Electrical and Computer Engineering